On a relative basis, the stock has outperformed the S&P 500 by 3.03% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.37% in the last 1 week, and is up 4.7% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -31.87% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $13.20 and the one year low was seen on May 13, 2016. The 50-Day Moving Average price is $7.81 and the 200 Day Moving Average price is recorded at $8.12.
The stock has recorded a 20-day Moving Average of 6.09% and the 50-Day Moving Average is 9.06%.
MiMedx Group Inc (NASDAQ:MDXG): stock turned positive on Friday. Though the stock opened at $8.17, the bulls momentum made the stock top out at $8.38 level for the day. The stock recorded a low of $8.07 and closed the trading day at $8.25, in the green by 1.73%. The total traded volume for the day was 682,516. The stock had closed at $8.11 in the previous days trading.
In an insider trading activity,The director officer (President and COO) of Mimedx Group, Inc., Taylor William Charles sold 24,333 shares at $7.52 on June 16, 2016. The Insider selling transaction had a total value worth of $182,984. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
MiMedx Group, Inc. (MiMedx) is an integrated developer, manufacturer and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The Companys biomaterial platform technologies include AmnioFix and EpiFix, its tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through its donor program, mothers delivering full-term Cesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce an implant, which is referred as an allograft. MiMedx is the supplier of amniotic tissue, having supplied over 350,000 allografts for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare. Its CollaFix technology combines a means of creating fibers from soluble collagen and a cross-linking process.